Back to Search
Start Over
Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.
- Source :
- Journal of Infectious Diseases; 2023 Supplement, Vol. 228, pS701-S711, 11p
- Publication Year :
- 2023
-
Abstract
- Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development of nonhuman primate (NHP) models of aerosol exposure. To address the potential threat of aerosol exposure, a monoclonal antibody that binds MARV glycoprotein was tested, MR186<subscript>YTE</subscript>, for its efficacy as a prophylactic. MR186<subscript>YTE</subscript> was administered intramuscularly to NHPs at 15 or 5 mg/kg 1 month prior to MARV aerosol challenge. Seventy-five percent (3/4) of the 15 mg/kg dose group and 50% (2/4) of the 5 mg/kg dose group survived. Serum analyses showed that the NHP dosed with 15 mg/kg that succumbed to infection developed an antidrug antibody response and therefore had no detectable MR186<subscript>YTE</subscript> at the time of challenge. These results suggest that intramuscular dosing of mAbs may be a clinically useful prophylaxis for MARV aerosol exposure. [ABSTRACT FROM AUTHOR]
- Subjects :
- MARBURG virus
MONOCLONAL antibodies
HEMORRHAGIC fever
PRIMATES
BLOOD serum analysis
Subjects
Details
- Language :
- English
- ISSN :
- 00221899
- Volume :
- 228
- Database :
- Complementary Index
- Journal :
- Journal of Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 173720576
- Full Text :
- https://doi.org/10.1093/infdis/jiad278